{"symbol":"REGN","fiscalQuarter":"Q1-2017","reportDate":"2017-05-04","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q1-2017","postBrief":{"headline":"Regeneron Pharmaceuticals Misses on EPS, Stock Up 6.7%","keyNumbers":[{"metric":"EPS","actual":"$2.92","expected":"N/A","surprise":"-10.51%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management expressed confidence in the long-term growth prospects of their pipeline.","They highlighted ongoing investments in research and development."],"summary":"Overall, management conveyed a positive outlook on future product launches despite the EPS miss. They emphasized the importance of innovation."},"guidanceChanges":{"summary":"No guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's earnings report showed a miss on EPS, yet the stock reacted positively, rising by 6.7%. Investors may be encouraged by management's focus on future growth and ongoing R&D investments. The lack of guidance might leave some uncertainty, but the overall tone suggests confidence in upcoming developments.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q1 2017 earnings: EPS missed expectations. Stock up 6.7%. Full breakdown."}}